Cargando...
Unveiling changes in the landscape of patient populations in cancer early drug development
The introduction of new Molecularly Targeted Agents (MTA) has changed the landscape in Early Drug Development (EDD) over the last two decades, leading to an improvement in clinical trial design. Previous Phase 1 (Ph1) studies with cytotoxics focused on safety objectives, only recruiting heavily pre-...
Guardado en:
| Publicado en: | Oncotarget |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Impact Journals LLC
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5355170/ https://ncbi.nlm.nih.gov/pubmed/27835915 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13258 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|